Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas

Composite lymphoma (COM) is an uncommon pathological diagnosis in which two or more distinct lymphomas are encountered within a single tissue sample. In contrast, discordant lymphoma (DIS) represents two or more distinct histologies encountered concurrently at two or more separate anatomic sites.

[1]  N. Bartlett,et al.  Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. , 2015, Blood.

[2]  K. Bendix,et al.  Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Cerhan,et al.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Angrilli,et al.  R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[6]  J. Connors,et al.  Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Cavalli,et al.  Incidence, risk factors and outcome of histological transformation in follicular lymphoma , 2012, British journal of haematology.

[8]  Andrew Lister,et al.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.

[9]  G. Salles,et al.  Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. , 2009, Journal of the National Cancer Institute.

[10]  M. Ghielmini,et al.  Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. , 2010, Journal of the National Cancer Institute.

[11]  R. Gascoyne,et al.  Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Randy D Gascoyne,et al.  Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Calaminici,et al.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Max Wolf,et al.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.

[15]  D. Arber,et al.  Bone Marrow Biopsy Involvement by Non-Hodgkin's Lymphoma: Frequency of Lymphoma Types, Patterns, Blood Involvement, and Discordance With Other Sites in 450 Specimens , 2005, American Journal of Surgical Pathology.